



**Avadel CNS Pharmaceuticals, LLC**

16640 Chesterfield Grove Road, Suite 200  
Chesterfield, Missouri 63005  
+1 (636) 449-1830  
avadel.com

To: The Office of the Attorney General

Subject: Notice to Vermont for introduction of LUMRYZ

Avadel CNS Pharmaceuticals, LLC has introduced the product (brand name LUMRYZ) to the market on 5/01/2023. The NDC, WAC and dosage information is provided below. Within 30 days of this notice, we will submit the full report using the “High-Cost Prescription Drug File Template”.

NDC	Description	WAC
<b>13551-001-07</b>	LUMRYZ 4.5 g (sodium oxybate) for extended-release oral suspension, #7 Each Powder in Packet	\$2,037.00
<b>13551-001-30</b>	LUMRYZ 4.5 g (sodium oxybate) for extended-release oral suspension, #30 Each Powder in Packet	\$8,730.02
<b>13551-002-07</b>	LUMRYZ 6.0 g (sodium oxybate) for extended-release oral suspension, #7 Each Powder in Packet	\$2,716.00
<b>13551-002-30</b>	LUMRYZ 6.0 g (sodium oxybate) for extended-release oral suspension, #30 Each Powder in Packet	\$11,640.02
<b>13551-003-07</b>	LUMRYZ 7.5 g (sodium oxybate) for extended-release oral suspension, #7 Each Powder in Packet	\$3,395.01
<b>13551-003-30</b>	LUMRYZ 7.5 g (sodium oxybate) for extended-release oral suspension, #30 Each Powder in Packet	\$14,550.03
<b>13551-004-07</b>	LUMRYZ 9.0 g (sodium oxybate) for extended-release oral suspension, #7 Each Powder in Packet	\$4,074.01
<b>13551-004-30</b>	LUMRYZ 9.0 g (sodium oxybate) for extended-release oral suspension, #30 Each Powder in Packet	\$17,460.03